BCO vs BMRN · P/E 25, rev $5.01B vs P/E 40, rev $2.85B
Brinks Company (BCO) versus Biomarin Pharmaceutical Inc (BMRN) — a side-by-side from cached financials, not a winner call.
Brinks Company (BCO) is a security & protection services company listed on US.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Latest reported BCO revenue for 2024-12-31 was $5.01B. Net income was $174.7M. Revenue was up 2.8% from 2023-12-31 to 2024-12-31. BCO currently screens at market cap $3.97B and trailing P/E 25.4.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
BCO currently screens at market cap $3.97B and trailing P/E 25.4. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Not investment advice. Open the BCO and BMRN stock pages for the full models.
Not investment advice.